Anti-Human TPO Monoclonal Antibody

High-dose cytarabine (HiDAC) consolidation for acute myeloid leukemia (AML) induces transient profound myelosuppression and potential morbidity/mortality. PrE0901 was a phase I multi-center trial evaluating the safety/toxicity of eltrombopag in AML patients receiving HiDAC consolidation. We used a standard 3 + 3 design employing a unique dose-escalation/de-escalation strategy. One hundred four patients were screened, 54 declined participation, 35 were deemed medically ineligible, and 14 were treated on study. Three patients were treated in cohorts 1-4 and two were treated in cohort 5. Eltrombopag + HiDAC was well-tolerated and no dose-limiting toxicities were observed. Median time to platelet recovery of all patients treated was 22.5 (range 16-43) days. Observationally, eltrombopag 150 mg once daily starting on day 3 of consolidation demonstrated the fastest and most consistent platelet recovery (median 19 days). Further investigation is needed to define the optimal role, dose, and schedule of eltrombopag in the treatment of chemotherapy associated myelosuppression.

Chronic spontaneous urticaria (CSU) lacks a specific trigger. The urticaria activity score (UAS) is used to evaluate disease status. Some studies have reported elevated serum levels of high-sensitivity C-reactive protein (hsCRP) in CSU patients, which is correlated with disease severity. The neutrophil/lymphocyte (N/L) ratio is a significant indicator of systemic inflammation. We investigated the potential correlation between serum levels of hsCRP and N/L ratio, as well as urticaria activity, in CSU patients. We included 52 CSU patients treated at the Dermatology Polyclinic of Beysehir State Hospital between August and October 2020, and 50 controls. The 7-day UAS were graded mild, moderate, or intense. We measured N/L ratios, erythrocyte sedimentation rates (ESRs), and the levels of hsCRP, T4, and thyroid-stimulating hormone (TSH) in each group. The anti-thyroglobulin (anti-TG) and anti-microsomal antibody (anti-TPO) levels of CSU patients were also assayed. There were no significant differences in hsCRP, T4, or TSH levels between the groups; however, both the ESR and N/L ratio were significantly higher in CSU patients hsCRP (P = .96), T4 (P = .07), TSH (P = .67), ESR (P < .001), N/L(P < .001). No correlation was evident between the UAS day 7 (UAS7) score and the hsCRP level or the N/L ratio (P = .528 and P = .387). Of all the CSU patients, 19.2% tested positive for anti-TPO and 9.6% were positive for anti-TG; these data were not correlated with the UAS7 (P = 1 and P = .637). Inflammation plays a role in CSU. Although we did not find a correlation between the UAS and either the hsCRP level or the N/L ratio, the ESR and N/L ratio were higher in CSU patients than in controls.